![](https://www.ema.europa.eu/sites/default/files/styles/ema_smp_opengraph/public/2024-07/EMA_building_202407_v1-copyright-EMA.png.webp?itok=TkkQ-6oh)
Human medicines European public assessment report (EPAR): Upstelda, ustekinumab, Status: Withdrawn application (before ...
The applicant withdrew the marketing authorisation application for Upstelda (ustekinumab) on 22 March 2024. It was a duplicate of the application for another medicine, Wezenla, which EMA’s human medicines committee (CHMP) was evaluating in parallel, and …